In this way, SGLT2 inhibitors demonstrate their efficacy in improving NAFLD by inhibiting upstream cellular signaling pathways involved in lipid accumulation in the liver and downstream cellular signaling pathways, influencing the activity of enzymes with a lipolytic effect. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.